EDIT-401
Hyperlipidemia and Atherosclerotic Cardiovascular Disease (ASCVD)
Pre-clinicalAdvancing to human proof-of-concept by end of 2026
Key Facts
Indication
Hyperlipidemia and Atherosclerotic Cardiovascular Disease (ASCVD)
Phase
Pre-clinical
Status
Advancing to human proof-of-concept by end of 2026
Company
About Editas Medicine
Editas Medicine is a leader in the CRISPR gene editing space, aiming to discover, develop, manufacture, and commercialize a robust pipeline of genomic medicines. The company leverages two distinct CRISPR nucleases, Cas9 and Cas12a, to access a broad range of genetic mutations and develop targeted in vivo therapies. Its strategic focus includes hemoglobinopathies, in vivo editing of hematopoietic stem cells and liver, and advancing cellular therapy assets through key partnerships with Bristol-Myers Squibb and Immatics N.V.
View full company profile